Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (807)	9/27/2005 5:41:38 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 1336

That second one is a textbook chapter which I cannot find. However, the KCN website at Scripps has a bunch of PDF's, so I will look at a review of total synthesis--with select examples from history! (including penicillin, rapamycin and taxol...) scripps.edu skipping through all the chemical diagrams, you come to a little bit about Drug Discovery and Development and Future Perspectives--"exotic natural productlike structures for the purpose of biological screening"

To: Mike McFarland who wrote (807)	9/27/2005 8:18:22 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

(reading Piggott and Peter Karuso reverse chemical proteomics) good grief, I remember "phage display"... nobelprize.org heh, "combinatorial biology" It seems inevitable that this process will at least occasionally outperform rational, knowledge-based design (I still cannot differentiate Anadys from a Kosan from a Diversa or any of the other hundreds of biotechs--but I'm having some fun here...so endulge me). Remember, I've looked at in recent years is shareholder's equity, and mostly just the cash... It is probably a good idea from time to time to delve into what these outfits actually do)